Raises FY25 revenue view to $768M-$793M from $756M-$776M, consensus $769.64M. Sees FY25 adjusted EBITDA $195M-$205M.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIP:
- ANI Pharmaceuticals Files Proxy for 2025 Meeting
- ANIP Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- ANI Pharmaceuticals presents preclinical data on use of Cortrophin Gel
- ANI Pharmaceuticals: Strategic Shift and Litigation Outcomes Poised to Drive Growth
- ANI Pharmaceuticals price target raised to $65 from $62 at Truist